ALSO NOTED: Qiagen acquires artus; Centocor gains priority review; Inverness buying diagnostic assets; and much more...

> Qiagen has acquired Germany's artus, which develops detection systems, for $39 million. Story

> The FDA has granted a priority review to Centocor's Remicade for ulcerative colitis. Release

> Inverness Medical is buying diagnostic assets from Abbott for $56.5 million. Release

> USA Today examines the current push to regulate drug marketing in America. Story

> The FDA has concurred with Spectrum Pharmaceuticals IND for SPI-153 and plans a Phase I/II clinical trial for prostate cancer. Release

> India's Ranbaxy has received a tentative nod from the FDA for a new HIV drug. Story

And Finally... A new study suggests that doctors are simply not prescribing cholesterol-lowering statins as frequently as needed. Story

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.